Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology

Bibliographic Details
Title: Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology
Authors: Filippo Merloni, Michela Palleschi, Caterina Gianni, Chiara Casadei, Annalisa Curcio, Antonino Romeo, Maddalena Rocchi, Simona Cima, Marianna Sirico, Samanta Sarti, Lorenzo Cecconetto, Marita Mariotti, Giandomenico Di Menna, Ugo De Giorgi
Source: Frontiers in Oncology, Vol 13 (2023)
Publisher Information: Frontiers Media S.A., 2023.
Publication Year: 2023
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: breast cancer, stage IV, primary tumor, locoregional treatment, surgery, radiotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Approximately 6% of metastatic breast cancers arise de novo. While systemic therapy (ST) remains the treatment backbone as for patients with metachronous metastases, locoregional treatment (LRT) of the primary tumor remains a controversial method. The removal of the primary has an established role for palliative purposes, but it is unclear if it could also determine a survival benefit. Retrospective evidence and pre-clinical studies seem to support the removal of the primary as an effective approach to improve survival. On the other hand, most randomized evidence suggests avoiding LRT. Both retrospective and prospective studies suffer several limitations, ranging from selection bias and outdated ST to a small sample of patients. In this review we discuss available data and try to identify subgroups of patients which could benefit the most from LRT of the primary, to facilitate clinical practice decisions, and to hypothesize future studies design on this topic.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2234-943X
Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1083297/full; https://doaj.org/toc/2234-943X
DOI: 10.3389/fonc.2023.1083297
Access URL: https://doaj.org/article/5b7a5769ddd3442daaf032bdb9c3abff
Accession Number: edsdoj.5b7a5769ddd3442daaf032bdb9c3abff
Database: Directory of Open Access Journals
More Details
ISSN:2234943X
DOI:10.3389/fonc.2023.1083297
Published in:Frontiers in Oncology
Language:English